• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

丙戊嗪在一名54岁重度迟发性运动障碍女性患者中的应用。

Use of Valbenazine in a 54-Year-Old Female with Severe Tardive Dyskinesia.

作者信息

Yee Maria Ruiza, Espiridion Eduardo D, Gurski John

机构信息

Psychiatry, Reading Hospital Tower Health, West Reading, USA.

出版信息

Cureus. 2020 Jan 28;12(1):e6801. doi: 10.7759/cureus.6801.

DOI:10.7759/cureus.6801
PMID:32140359
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7045975/
Abstract

Tardive dyskinesia (TD) is a serious and often irreversible involuntary muscle movement that involves the face, lips, tongue, trunk, and extremities. TD is a risk in the use of antipsychotic medications, whether it is typical or first generation or atypical or second-generation antipsychotic. The risk is highest in patients receiving long-term antipsychotic treatment. Before the availability of valbenazine, clozapine was used to reverse or at least ameliorate TD. We report a case of a patient on long-term antipsychotic treatment whose TD was initially reversed by clozapine but was completely reversed by valbenazine.

摘要

迟发性运动障碍(TD)是一种严重且通常不可逆的不自主肌肉运动,累及面部、嘴唇、舌头、躯干和四肢。使用抗精神病药物会有TD的风险,无论是典型(第一代)还是非典型(第二代)抗精神病药物。接受长期抗精神病治疗的患者风险最高。在缬苯那嗪问世之前,氯氮平被用于逆转或至少改善TD。我们报告一例长期接受抗精神病治疗的患者,其TD最初通过氯氮平得到逆转,但最终通过缬苯那嗪完全逆转。

相似文献

1
Use of Valbenazine in a 54-Year-Old Female with Severe Tardive Dyskinesia.丙戊嗪在一名54岁重度迟发性运动障碍女性患者中的应用。
Cureus. 2020 Jan 28;12(1):e6801. doi: 10.7759/cureus.6801.
2
Atypical Antipsychotic-Induced Tardive Dyskinesia in a Middle-Aged Schizophrenic Patient: A Case Report.一名中年精神分裂症患者出现非典型抗精神病药物所致迟发性运动障碍:病例报告
Cureus. 2024 Jul 29;16(7):e65663. doi: 10.7759/cureus.65663. eCollection 2024 Jul.
3
Diagnostic and Treatment Fundamentals for Tardive Dyskinesia.迟发性运动障碍的诊断与治疗基础
J Clin Psychiatry. 2021 Oct 12;82(6):NU20016AX1C. doi: 10.4088/JCP.NU20016AX1C.
4
The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder.盐酸胍法辛治疗首发心境障碍患者迟发性运动障碍的效果。
J Affect Disord. 2019 Mar 1;246:217-223. doi: 10.1016/j.jad.2018.12.023. Epub 2018 Dec 17.
5
Tardive Dyskinesia With Chorea-Ballism Improved by Valbenazine: A Case Report.丙戊嗪改善迟发性运动障碍伴舞蹈症-手足徐动症:一例报告
Cureus. 2024 Feb 22;16(2):e54666. doi: 10.7759/cureus.54666. eCollection 2024 Feb.
6
Relapse of tardive dyskinesia due to reduction in clozapine dose.氯氮平剂量减少致迟发性运动障碍复发。
Indian J Pharmacol. 2009 Aug;41(4):201-2. doi: 10.4103/0253-7613.56067.
7
KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.KINECT 3 试验:坎非丁治疗迟发性运动障碍的 3 期随机、双盲、安慰剂对照试验
Am J Psychiatry. 2017 May 1;174(5):476-484. doi: 10.1176/appi.ajp.2017.16091037. Epub 2017 Mar 21.
8
Valbenazine for the treatment of tardive dyskinesia.用于治疗迟发性运动障碍的氘代丁苯那嗪
Expert Opin Pharmacother. 2017 Aug;18(12):1279-1287. doi: 10.1080/14656566.2017.1353078. Epub 2017 Aug 2.
9
The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study.盐酸胍法辛治疗迟发性运动障碍患者的疗效:为期 1 年的 KINECT 3 扩展研究结果。
J Clin Psychiatry. 2017 Nov/Dec;78(9):1344-1350. doi: 10.4088/JCP.17m11777.
10
Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.缬苯那嗪(NBI-98854)在患有迟发性运动障碍且诊断为精神分裂症或心境障碍的受试者中的长期安全性和耐受性。
Psychopharmacol Bull. 2017 Aug 1;47(3):61-68.

本文引用的文献

1
Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies.与非典型抗精神病药物相关的迟发性运动障碍:患病率、发病机制和管理策略。
CNS Drugs. 2018 Feb;32(2):135-147. doi: 10.1007/s40263-018-0494-8.
2
Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment.迟发性运动障碍的流行病学、预防、评估及治疗进展
J Clin Psychiatry. 2017 Sep/Oct;78(8):1136-1147. doi: 10.4088/JCP.tv17016ah4c.
3
Medication-Induced Tardive Dyskinesia: A Review and Update.药物性迟发性运动障碍:综述与更新
Ochsner J. 2017 Summer;17(2):162-174.
4
NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.NBI-98854,一种用于治疗迟发性运动障碍的选择性单胺转运抑制剂:一项随机、双盲、安慰剂对照研究。
Mov Disord. 2015 Oct;30(12):1681-7. doi: 10.1002/mds.26330. Epub 2015 Sep 8.
5
Clozapine and tardive dyskinesia.氯氮平和迟发性运动障碍。
J Clin Psychiatry. 2002 Feb;63(2):167-8. doi: 10.4088/jcp.v63n0213d.
6
Tardive dyskinesia, clozapine, and treatment response.迟发性运动障碍、氯氮平与治疗反应
Prog Neuropsychopharmacol Biol Psychiatry. 1998 May;22(4):567-73. doi: 10.1016/s0278-5846(98)00026-8.
7
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.氯氮平用于难治性精神分裂症。与氯丙嗪的双盲对照研究。
Arch Gen Psychiatry. 1988 Sep;45(9):789-96. doi: 10.1001/archpsyc.1988.01800330013001.